Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma
Source: OncLive, November 2023
Experts discuss a preference for ipilimumab/nivolumab as the frontline immunotherapy for patients with BRAF-mutant metastatic melanoma given its proven long-term efficacy but acknowledge nivolumab/relatlimab as an option with less toxicity, especially adrenal insufficiency.
